A detailed history of Blair William & CO transactions in Exact Sciences Corp stock. As of the latest transaction made, Blair William & CO holds 357,811 shares of EXAS stock, worth $20.8 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
357,811
Previous 446,686 19.9%
Holding current value
$20.8 Million
Previous $18.9 Million 29.1%
% of portfolio
0.07%
Previous 0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$42.43 - $70.83 $3.77 Million - $6.3 Million
-88,875 Reduced 19.9%
357,811 $24.4 Million
Q2 2024

Aug 12, 2024

BUY
$41.33 - $74.26 $4.13 Million - $7.41 Million
99,817 Added 28.78%
446,686 $18.9 Million
Q1 2024

May 09, 2024

SELL
$56.27 - $73.77 $1.29 Million - $1.7 Million
-22,988 Reduced 6.22%
346,869 $24 Million
Q4 2023

Feb 12, 2024

SELL
$59.06 - $75.72 $488,544 - $626,355
-8,272 Reduced 2.19%
369,857 $27.4 Million
Q3 2023

Nov 09, 2023

SELL
$65.94 - $99.04 $566,226 - $850,456
-8,587 Reduced 2.22%
378,129 $25.8 Million
Q2 2023

Aug 11, 2023

SELL
$62.68 - $95.05 $233,169 - $353,586
-3,720 Reduced 0.95%
386,716 $36.3 Million
Q1 2023

May 12, 2023

SELL
$47.19 - $70.77 $1.04 Million - $1.56 Million
-22,022 Reduced 5.34%
390,436 $26.5 Million
Q4 2022

Feb 10, 2023

SELL
$30.35 - $53.15 $64,311 - $112,624
-2,119 Reduced 0.51%
412,458 $20.4 Million
Q3 2022

Nov 09, 2022

SELL
$31.97 - $49.37 $986,690 - $1.52 Million
-30,863 Reduced 6.93%
414,577 $13.5 Million
Q2 2022

Aug 10, 2022

SELL
$35.61 - $76.23 $11.1 Million - $23.8 Million
-311,563 Reduced 41.16%
445,440 $17.5 Million
Q1 2022

May 13, 2022

BUY
$57.56 - $82.54 $7.21 Million - $10.3 Million
125,339 Added 19.84%
757,003 $52.9 Million
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $1.68 Million - $2.34 Million
-23,238 Reduced 3.55%
631,664 $49.2 Million
Q3 2021

Nov 12, 2021

SELL
$90.24 - $124.05 $4.2 Million - $5.77 Million
-46,507 Reduced 6.63%
654,902 $62.5 Million
Q2 2021

Aug 12, 2021

SELL
$93.66 - $139.27 $2.2 Million - $3.27 Million
-23,480 Reduced 3.24%
701,409 $87.2 Million
Q1 2021

May 13, 2021

BUY
$116.57 - $155.01 $4.35 Million - $5.79 Million
37,322 Added 5.43%
724,889 $95.5 Million
Q4 2020

Feb 09, 2021

SELL
$99.61 - $142.12 $360,090 - $513,763
-3,615 Reduced 0.52%
687,567 $91.1 Million
Q3 2020

Nov 06, 2020

BUY
$72.92 - $102.01 $649,644 - $908,807
8,909 Added 1.31%
691,182 $70.5 Million
Q2 2020

Aug 12, 2020

SELL
$55.75 - $92.75 $5.08 Million - $8.46 Million
-91,203 Reduced 11.79%
682,273 $59.3 Million
Q1 2020

May 11, 2020

SELL
$37.9 - $104.44 $10.2 Million - $28.1 Million
-269,065 Reduced 25.81%
773,476 $44.9 Million
Q4 2019

Feb 13, 2020

BUY
$77.66 - $99.74 $12.4 Million - $15.9 Million
159,812 Added 18.1%
1,042,541 $96.4 Million
Q3 2019

Nov 12, 2019

BUY
$90.37 - $122.49 $8.36 Million - $11.3 Million
92,540 Added 11.71%
882,729 $79.8 Million
Q2 2019

Aug 13, 2019

SELL
$89.51 - $118.04 $112,424 - $148,258
-1,256 Reduced 0.16%
790,189 $93.3 Million
Q1 2019

May 14, 2019

BUY
$61.98 - $96.5 $129,104 - $201,009
2,083 Added 0.26%
791,445 $68.6 Million
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $1.07 Million - $1.59 Million
19,182 Added 2.49%
789,362 $49.8 Million
Q3 2018

Nov 13, 2018

BUY
$48.29 - $80.6 $6.61 Million - $11 Million
136,803 Added 21.6%
770,180 $60.8 Million
Q2 2018

Aug 13, 2018

SELL
$37.84 - $69.96 $1.18 Million - $2.18 Million
-31,161 Reduced 4.69%
633,377 $37.9 Million
Q1 2018

May 15, 2018

BUY
$39.82 - $57.53 $2.28 Million - $3.29 Million
57,225 Added 9.42%
664,538 $26.8 Million
Q4 2017

Feb 14, 2018

SELL
$46.49 - $60.51 $1.85 Million - $2.41 Million
-39,803 Reduced 6.15%
607,313 $31.9 Million
Q3 2017

Nov 13, 2017

BUY
$37.05 - $47.12 $24 Million - $30.5 Million
647,116
647,116 $30.5 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.